Inclusion Criteria:

- Age ≥ 18 years

- Histologic proof of melanoma reviewed and confirmed at MSKCC

- Patients must have stage IV melanoma or recurrent stage IIIb or IIIc melanoma.
Patients who are potentially respectable will be eligible.

- Measurable disease (RECIST criteria). Patients must have a tumor amenable to biopsy
for oligonucleotide microarray analysis and for immunohistochemistry. A pre-treatment
biopsy is required; a fine needle aspirate is not adequate.

- No prior cytotoxic chemotherapy for melanoma. Prior immunotherapy or anti-angiogenic
therapy is allowed.

- No other concurrent chemotherapy, immunotherapy, or radiotherapy

- ECOG performance status ≤ 1

- Adequate organ function defined as follows: ANC >1500/mm3, Platelets >130,000/mm3,
calculated creatinine clearance ≥60 ml/minute (Cockcroft & Gault).

- Adequate cardiac function to tolerate the hydration needed for cisplatin
administration.

Exclusion Criteria:

- History of CNS metastases unless brain metastases have been resected or successfully
treated with stereotactic radiosurgery and the patient has been free from CNS
recurrence for 3 months.

- Uveal melanoma primary

- Patients who have had prior anti-CTLA4 monoclonal antibody treatment must have been
off treatment for at least 4 months and have signs of progression of disease.

- Frequent vomiting or medical conditions that could interfere with oral medication
intake

- Serious infection requiring antibiotics, or nonmalignant medical illnesses that are
uncontrolled or whose control might be jeopardized by the complications of this
therapy.

- History of HIV infection even if on HAART

- Immunosuppressive drugs

- High dose vitamins and herbs

- Other on-going investigational therapy, concurrent chemotherapy, immunotherapy or
radiotherapy.